Exact Mass: 433.1671
Exact Mass Matches: 433.1671
Found 500 metabolites which its exact mass value is equals to given mass value 433.1671
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Meleagrine
An indole alkaloid with a heterotetracyclic skeleton isolated from Penicillium oxalicum.
4-Hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine
4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine is an acylcarnitine. More specifically, it is an 4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2R)-1-[4-[1,3-Benzothiazol-2-yl(methyl)amino]piperidin-1-yl]-3-(3,4-difluorophenoxy)propan-2-ol
8-[[(1R)-1-(3,4-Dimethoxyphenyl)-2-hydroxyethyl]amino]-7-(2-methoxyethyl)-1,3-dimethylpurine-2,6-dione
Arg-gly-asp-ser
Brexpiprazole
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[1][2].
(2S)-2-[[4-[[(2R)-2-Amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid
2-Methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D000970 - Antineoplastic Agents
4-Nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate
1-(2-Methyl-4-methoxyphenyl)-4-((2-hydroxyethyl)amino)-6-trifluoromethoxy-2,3-dihydropyrrolo(3,2-c)quinoline
D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors
Sarpicillin
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
N-(((1-(2-(Diethylamino)ethyl)amino)-9-oxo-9H-thioxanthen-4-yl)methyl)methanesulfonamide
L-Alanine, 3-(((3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, (R)-
Fenfangjine G
Nitrile,1-O-beta-rutinoside-glucopyranoside,penta-Ac-1,4-Dihydroxy-2-cyclopentene-1-carboxylic acid
(3,5-Isomer,6-oxo,N-Me-Gerambullin|Methylisogerambullone|methylisogerammbullone|MIGB
(1R)-(4-hydroxybenzyl)-7-hydroxyl-8-O-beta-D-glucopyranosyl-1,2,3,4-tetrahydroisoquinoline
6-Oxo,N-Me-Gerambullin|Methylgerambullone|methylgerammbullone
(-)-8alpha-(4-methoxybenzyl)-2-methoxyberbin-3,10,11-triol|(-)-8alpha-<4-methoxybenzyl>-2-methoxyberbin-3,10,11-triol|O4-Me-8-(4-Hydroxybenzyl)-2-methoxy-3,10,11-berbintriol
Ala Asn Asp Asp
12-[(2,4-dimethoxyphenyl)carbonyl]-6a,6b,10,11,11a,12-hexahydro-8,11-epoxyoxepino[4,5:3,4]pyrrolo[1,2-a]quinolin-7(8H)-one
relative retention time with respect to 9-anthracene Carboxylic Acid is 1.276 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.275 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.279
[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate
C23H23N5O4_(3Z)-6-Hydroxy-3-(1H-imidazol-5-ylmethylene)-12-methoxy-7a-(2-methyl-3-buten-2-yl)-7a,12-dihydro-1H,5H-imidazo[1,2:1,2]pyrido[2,3-b]indole-2,5(3H)-dione
[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate [IIN-based on: CCMSLIB00000846974]
[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate [IIN-based: Match]
Ala Asp Asp Asn
Ala Asp Asn Asp
Ala Asp Gln Thr
Ala Asp Thr Gln
Ala Glu Asn Thr
Ala Glu Gln Ser
Ala Glu Ser Gln
Ala Glu Thr Asn
Ala Asn Glu Thr
Ala Asn Thr Glu
Ala Gln Asp Thr
Ala Gln Glu Ser
Ala Gln Ser Glu
Ala Gln Thr Asp
Ala Ser Glu Gln
Ala Ser Gln Glu
Ala Thr Asp Gln
Ala Thr Glu Asn
Ala Thr Asn Glu
Ala Thr Gln Asp
Cys Asn Pro Thr
Cys Asn Thr Pro
Cys Pro Asn Thr
Cys Pro Gln Ser
Cys Pro Ser Gln
Cys Pro Thr Asn
Cys Gln Pro Ser
Cys Gln Ser Pro
Cys Ser Pro Gln
Cys Ser Gln Pro
Cys Thr Asn Pro
Cys Thr Pro Asn
Asp Ala Asp Asn
Asp Ala Asn Asp
Asp Ala Gln Thr
Asp Ala Thr Gln
Asp Asp Ala Asn
Asp Asp Gly Lys
Asp Asp Gly Gln
Asp Asp Lys Gly
Asp Asp Asn Ala
Asp Asp Gln Gly
Asp Glu Gly Asn
Asp Glu Asn Gly
Asp Gly Asp Lys
Asp Gly Asp Gln
Asp Gly Glu Asn
Asp Gly Gly Trp
Asp Gly Lys Asp
Asp Gly Asn Glu
Asp Gly Gln Asp
Asp Gly Arg Ser
Asp Gly Ser Arg
Asp Gly Trp Gly
Asp Lys Asp Gly
Asp Lys Gly Asp
Asp Asn Ala Asp
Asp Asn Asp Ala
Asp Asn Glu Gly
Asp Asn Gly Glu
Asp Asn Ser Val
Asp Asn Val Ser
Asp Gln Ala Thr
Asp Gln Asp Gly
Asp Gln Gly Asp
Asp Gln Thr Ala
Asp Arg Gly Ser
Asp Arg Ser Gly
Asp Ser Gly Arg
Asp Ser Asn Val
Asp Ser Arg Gly
Asp Ser Val Asn
Asp Thr Ala Gln
Asp Thr Gln Ala
Asp Val Asn Ser
Asp Val Ser Asn
Asp Trp Gly Gly
Glu Ala Asn Thr
Glu Ala Gln Ser
Glu Ala Ser Gln
Glu Ala Thr Asn
Glu Asp Gly Asn
Glu Asp Asn Gly
Glu Gly Asp Asn
Glu Gly Asn Asp
Glu Gly Gln Thr
Glu Gly Thr Gln
Glu Asn Ala Thr
Glu Asn Asp Gly
Glu Asn Gly Asp
Glu Asn Thr Ala
Glu Gln Ala Ser
Glu Gln Gly Thr
Glu Gln Ser Ala
Glu Gln Thr Gly
Glu Ser Ala Gln
Glu Ser Gln Ala
Glu Thr Ala Asn
Glu Thr Gly Gln
Glu Thr Asn Ala
Glu Thr Gln Gly
Gly Asp Asp Lys
Gly Asp Asp Gln
Gly Asp Glu Asn
Gly Asp Gly Trp
Gly Asp Lys Asp
Gly Asp Asn Glu
Gly Asp Gln Asp
Gly Asp Arg Ser
Gly Asp Ser Arg
Gly Asp Trp Gly
Gly Glu Asp Asn
Gly Glu Asn Asp
Gly Glu Gln Thr
Gly Glu Thr Gln
Gly Gly Asp Trp
Gly Gly Trp Asp
Gly Lys Asp Asp
Gly Asn Asp Glu
Gly Asn Glu Asp
Gly Gln Asp Asp
Gly Gln Glu Thr
Gly Gln Thr Glu
Gly Arg Asp Ser
Gly Arg Ser Asp
Gly Ser Asp Arg
Gly Ser Arg Asp
Gly Thr Glu Gln
Gly Thr Gln Glu
Gly Trp Asp Gly
Gly Trp Gly Asp
Lys Asp Asp Gly
Lys Asp Gly Asp
Lys Gly Asp Asp
Asn Ala Asp Asp
Asn Ala Glu Thr
Asn Ala Thr Glu
Asn Cys Pro Thr
Asn Cys Thr Pro
Asn Asp Ala Asp
Asn Asp Asp Ala
Asn Asp Glu Gly
Asn Asp Gly Glu
Asn Asp Ser Val
Asn Asp Val Ser
Asn Glu Ala Thr
Asn Glu Asp Gly
Asn Glu Gly Asp
Asn Glu Thr Ala
Asn Gly Asp Glu
Asn Gly Glu Asp
Asn Pro Cys Thr
Asn Pro Thr Cys
Asn Ser Asp Val
Asn Ser Val Asp
Asn Thr Ala Glu
Asn Thr Cys Pro
Asn Thr Glu Ala
Asn Thr Pro Cys
Asn Val Asp Ser
Asn Val Ser Asp
Pro Cys Asn Thr
Pro Cys Gln Ser
Pro Cys Ser Gln
Pro Cys Thr Asn
Pro Asn Cys Thr
Pro Asn Thr Cys
Pro Gln Cys Ser
Pro Gln Ser Cys
Pro Ser Cys Gln
Pro Ser Gln Cys
Pro Thr Cys Asn
Pro Thr Asn Cys
Gln Ala Asp Thr
Gln Ala Glu Ser
Gln Ala Ser Glu
Gln Ala Thr Asp
Gln Cys Pro Ser
Gln Cys Ser Pro
Gln Asp Ala Thr
Gln Asp Asp Gly
Gln Asp Gly Asp
Gln Asp Thr Ala
Gln Glu Ala Ser
Gln Glu Gly Thr
Gln Glu Ser Ala
Gln Glu Thr Gly
Gln Gly Asp Asp
Gln Gly Glu Thr
Gln Gly Thr Glu
Gln Pro Cys Ser
Gln Pro Ser Cys
Gln Ser Ala Glu
Gln Ser Cys Pro
Gln Ser Glu Ala
Gln Ser Pro Cys
Gln Thr Ala Asp
Gln Thr Asp Ala
Gln Thr Glu Gly
Gln Thr Gly Glu
Arg Asp Gly Ser
Arg Asp Ser Gly
Arg Gly Asp Ser
Arg Gly Ser Asp
Arg Ser Asp Gly
Arg Ser Gly Asp
Ser Ala Glu Gln
Ser Ala Gln Glu
Ser Cys Pro Gln
Ser Cys Gln Pro
Ser Asp Gly Arg
Ser Asp Asn Val
Ser Asp Arg Gly
Ser Asp Val Asn
Ser Glu Ala Gln
Ser Glu Gln Ala
Ser Gly Asp Arg
Ser Gly Arg Asp
Ser Asn Asp Val
Ser Asn Val Asp
Ser Pro Cys Gln
Ser Pro Gln Cys
Ser Gln Ala Glu
Ser Gln Cys Pro
Ser Gln Glu Ala
Ser Gln Pro Cys
Ser Arg Asp Gly
Ser Arg Gly Asp
Ser Val Asp Asn
Ser Val Asn Asp
Thr Ala Asp Gln
Thr Ala Glu Asn
Thr Ala Asn Glu
Thr Ala Gln Asp
Thr Cys Asn Pro
Thr Cys Pro Asn
Thr Asp Ala Gln
Thr Asp Gln Ala
Thr Glu Ala Asn
Thr Glu Gly Gln
Thr Glu Asn Ala
Thr Glu Gln Gly
Thr Gly Glu Gln
Thr Gly Gln Glu
Thr Asn Ala Glu
Thr Asn Cys Pro
Thr Asn Glu Ala
Thr Asn Pro Cys
Thr Pro Cys Asn
Thr Pro Asn Cys
Thr Gln Ala Asp
Thr Gln Asp Ala
Thr Gln Glu Gly
Thr Gln Gly Glu
Val Asp Asn Ser
Val Asp Ser Asn
Val Asn Asp Ser
Val Asn Ser Asp
Val Ser Asp Asn
Val Ser Asn Asp
Trp Asp Gly Gly
Trp Gly Asp Gly
Trp Gly Gly Asp
6-(methylamino)hexane-1,2,3,4,5-pentol,4-(2H-tetrazol-5-yl)tetrazolo[1,5-a]quinoline
1H-Pyrazole-4-carboxamide,5-chloro-N-[2-[(3,7-dimethyl-2-quinolinyl)amino]ethyl]-3-methyl-1-phenyl-(9CI)
4-BROMO-N-DODECYL-1-HYDROXY-2-NAPHTHALENECARBOXAMIDE
(4R,12aS)-N-(2,4-Difluorobenzyl)-7-Methoxy-4-Methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-9-carboxamide
Sarpicillin
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
3-[[4-(diethylamino)phenyl]azo]-1,2-dimethyl-1H-indazolium methyl sulphate
Arg-Gly-Asp-Ser
Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
Thiourea, N-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-N-(4-fluorophenyl)-N-(3-pyridinylmethyl)- (9CI)
2-[2-[4-[(2-chloroethyl)methylamino]phenyl]vinyl]-1,3,3-trimethyl-3H-indolium dihydrogen phosphate
9-AMino-(9-deoxy)epi-dihydroquinine trihydrochloride
(5aS,10bR)-2-(2,6-Diethylphenyl)-5a,10b-dihydro-4H,6Hindeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Tetrafluoroborate,99e.e.
(5aR,10bS)-2-(2,6-Diethylphenyl)-5a,10b-dihydro-4H,6Hindeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Tetrafluoroborate
(S)-(4-(3-(BENZYLOXY)-2-(((BENZYLOXY)CARBONYL)AMINO)-3-OXOPROPYL)PHENYL)BORONIC ACID
Methyl (3R,4S)-1-(4-fluorophenyl)-2-oxo-4-[4-(phenylmethoxy)phenyl]-3-azetidinepropanoate
Hydroxychloroquine sulfate
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018501 - Antirheumatic Agents D004791 - Enzyme Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Fluvastatin sodium
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor (3S,5R)-Fluvastatin sodium ((3S,5R)-XU 62-320) is the (3S,5R)-enantiomer?of Fluvastatin. Fluvastatin is a first fully synthetic, competitive?HMG-CoA reductase?inhibitor with an IC50?of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1].
Lubeluzole
D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D002317 - Cardiovascular Agents D020011 - Protective Agents
(4-Nitrophenyl) 4-[(3-phenoxyphenyl)methyl]piperazine-1-carboxylate
JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively[1].
N-(((1-(2-(Diethylamino)ethyl)amino)-9-oxo-9H-thioxanthen-4-yl)methyl)methanesulfonamide
1-(4-(Benzo[d]thiazol-2-yl(methyl)amino)piperidin-1-yl)-3-(3,4-difluorophenoxy)propan-2-ol
(3r,5s)-Fluvastatin sodium
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors (3R,5S)-Fluvastatin ((3R,5S)-XU 62-320) sodium is the 3R,5S-isomer Fluvastatin. Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1][2][3].
(2S)-2-[[4-[[(2R)-2-Amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid
N-(3-chloropyridin-2-yl)-N-[(3R)-piperidin-3-yl]-4-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)benzamide
N-(2,4-dimethoxyphenyl)-2-[1-(3,4-dimethylphenyl)-4-oxo-5-pyrazolo[3,4-d]pyrimidinyl]acetamide
5-[(3,4-Dimethoxyphenyl)-[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-2-methyl-6-thiazolo[3,2-b][1,2,4]triazolol
Brexpiprazole
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[1][2].
(2S)-2-[[4-[[(2R)-2-Amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid
(3Z)-3-[(2E,4E,6R)-1-hydroxy-6-[(2S,7R,8R)-2-(hydroxymethyl)-1,7-dimethyl-5-oxo-3,9,10-trioxatricyclo[4.3.1.02,4]decan-8-yl]-4-methylhepta-2,4-dienylidene]pyrrolidine-2,4-dione
4-Hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine
(3E,7aS,12aR)-6-hydroxy-3-(1H-imidazol-4-ylmethylidene)-12-methoxy-7a-(2-methylbut-3-en-2-yl)-7a,12-dihydro-1H,5H-imidazo[1,2:1,2]pyrido[2,3-b]indole-2,5(3H)-dione
N-{4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl}-2-methylpropanamide
4-chloro-N-[2-(1H-indol-3-yl)-1-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)ethyl]benzamide
3-(3,4,5-Trimethoxyphenyl)propanoic acid [2-(3,5-dimethoxyanilino)-2-oxoethyl] ester
2-[[7-(4-Methoxyphenyl)-5-phenyl-4-pyrrolo[2,3-d]pyrimidinyl]thio]propanoic acid ethyl ester
3-[2-[(1,5-Dimethyl-3-oxo-2-phenyl-4-pyrazolyl)amino]-2-oxoethyl]-4-oxo-1-phthalazinecarboxylic acid
[1-[1-[4-(difluoromethoxy)phenyl]-2,5-dimethylpyrrol-3-yl]-1-oxopropan-2-yl] 6-oxo-4,5-dihydro-1H-pyridazine-3-carboxylate
7-[(2-Chloro-6-fluorophenyl)methyl]-1,3-dimethyl-8-[(3-methyl-1-piperidinyl)methyl]purine-2,6-dione
2-[(5,5-dimethyl-6H-[1,2,4]triazolo[3,4-a]isoquinolin-3-yl)thio]-1-(4-phenyl-1-piperazinyl)ethanone
1-(4-methylphenyl)-3-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]thiourea
N-(2,5-dimethoxyphenyl)sulfonyl-N-(4-methoxyphenyl)cyclohexanecarboxamide
4-[2-Benzofuranyl(oxo)methyl]-1-[2-(4-morpholinyl)ethyl]-5-(3-pyridinyl)pyrrolidine-2,3-dione
(2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
N-[(2R,3S,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
N-[(2R,3R,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
2-[(2R,3S,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2S,3S,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2R,3R,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
N-[(2R,3S,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
(1R,2aS,8bS)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1R,2aR,8bR)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1R,9S,10S,11S)-N-benzyl-5-(3-fluorophenyl)-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
[(2S,3R)-1-[(4-chlorophenyl)methyl]-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-(3-pyridinyl)methanone
[(2S,3S)-1-[(4-chlorophenyl)methyl]-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-(3-pyridinyl)methanone
N-[(2R,3R,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
N-[(2S,3S,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
N-[(2S,3S,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
2-[(2S,3R,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2S,3R,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2R,3S,6R)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
2-[(2R,3R,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(4-pyrimidinylmethyl)acetamide
N-[(2S,3R,6S)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
N-[(2S,3R,6R)-6-[2-[[(4-chloroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyrazinecarboxamide
(1S,2aR,8bR)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1S,2aS,8bS)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-N-phenyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1S,9R,10R,11R)-N-benzyl-5-(3-fluorophenyl)-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
cyclobutyl-[(1S)-1-(hydroxymethyl)-7-methoxy-1-methylsulfonyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanone
[(2R,3R)-1-[(4-chlorophenyl)methyl]-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-(3-pyridinyl)methanone
cyclobutyl-[(1R)-1-(hydroxymethyl)-7-methoxy-1-methylsulfonyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanone
5-(3,4-Dimethoxyphenyl)-4-(furan-2-carbonyl)-1-(2-phenylethyl)pyrrolidine-2,3-dione
Fluvastatin (sodium)
Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin sodium protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1][2][3].
G907
G907 is a selective antagonist of ATP-binding cassette (ABC) transporter MsbA with anti-microbial activity. G907 inhibits E. coli MsbA with an IC50 value of 18 nM. G907 traps MsbA in an inward-facing, lipopolysaccharide-bound conformation by wedging into an architecturally conserved transmembrane pocket[1][2].
Izilendustat
Izilendustat is a potent inhibitor of prolyl hydroxylase which can stabilize hypoxia inducible factor- 1 alpha (HIF- lα) and hypoxia inducible factor-2 (HIF-2). Izilendustat has the potential for researching diseases that relate to the body’s inmmune response like colitis and other inflammatory bowel diseases (extracted from patent WO2011057115A1 and WO2011057121A1)[1][1].
PHT-7.3
PHT-7.3 is a selective inhibitor of connector enhancer of kinase suppressor of Ras 1 (Cnk1) pleckstrin homology (PH) domain (Kd=4.7 μM). PHT-7.3 inhibits mut-KRas, but not wild-type KRas cancer cell and tumor growth and signaling. PHT-7.3 has antitumor activity[1].